Aethlon Medical, Inc. Q1 FY2026 earnings call

• Progress in Australian oncology trial: Completed first cohort, DSMB recommended advancing to second cohort. • Decided not to proceed with India oncology trial due to extended timeline and strategic focus, expecting to conserve $500,000 to $1 million. • Preclinical results supporting broader applications including long COVID, presented data at Keystone Symposium. • Preclinical ex vivo study showed 98.5% removal of platelet-derived EVs from plasma using Aethlon Hemopurifier. • Focus on moving Hemopurifier towards regulatory approval and expanding use across multiple diseases.

• Based on progress in Australia, could complete treatments by late 2025/early 2026, analyze data, and apply for PMA or efficacy trial. • Actively working to speed up enrollment in Australian trial through measures like prescreening logs, additional sites, clinical trial liaisons, and social media campaigns.

• Risk of delays if still early in Indian trial affecting path forward with regulators or strategic partners. • General risks associated with clinical trial outcomes and regulatory approvals for the Hemopurifier.

Q: Is the progress in the Australian oncology trial such that we're on track to meet the primary endpoint?

A: Yes, the independent Data Safety Monitoring Board reviewed safety data and recommended advancing to the second cohort, indicating progress towards the primary endpoint.

Q: Thoughts on preclinical data vs actual clinical study data?

A: Preclinical data in lab is not the same as actual patient study data; the proof is in what happens with actual patients, and efforts are underway to get data from the Grau lab.

Q: Reason for setting up parallel Indian trial and plans to speed up enrollment in Australia?

A: Reason for Indian trial was initial setup; efforts to speed up enrollment in Australia include prescreening logs, additional sites, clinical trial liaisons, and social media campaigns